DDInter1035 DDInter604
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy and during the postpartum period, and this should be considered when assessing potential risks of hormonal contraceptive use.
Lenalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) causes {v} (Side Effect) Venous thromboembolism
Venous thromboembolism {u} (Side Effect) is caused by {v} (Compound) Methyltestosterone
Methyltestosterone {u} (Compound) resembles {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) upregulates {v} (Gene) JADE2
JADE2 {u} (Gene) is upregulated by {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) upregulates {v} (Gene) JADE2
JADE2 {u} (Gene) is regulated by {v} (Gene) AR
AR {u} (Gene) is bound by {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) upregulates {v} (Gene) SQRDL
SQRDL {u} (Gene) is upregulated by {v} (Compound) Medrysone
Medrysone {u} (Compound) resembles {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Medrysone
Medrysone {u} (Compound) resembles {v} (Compound) Drospirenone
Lenalidomide {u} (Compound) downregulates {v} (Gene) GDF15
GDF15 {u} (Gene) is regulated by {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Drospirenone
Lenalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Drospirenone (Compound)
Lenalidomide (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Drospirenone (Compound)
Lenalidomide (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Hydrocortisone (Compound) and Hydrocortisone (Compound) resembles Drospirenone (Compound)
Lenalidomide (Compound) causes Venous thromboembolism (Side Effect) and Venous thromboembolism (Side Effect) is caused by Methyltestosterone (Compound) and Methyltestosterone (Compound) resembles Drospirenone (Compound)
Lenalidomide (Compound) upregulates JADE2 (Gene) and JADE2 (Gene) is upregulated by Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Lenalidomide (Compound) upregulates JADE2 (Gene) and JADE2 (Gene) is regulated by AR (Gene) and AR (Gene) is bound by Drospirenone (Compound)
Lenalidomide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Lenalidomide (Compound) upregulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Medrysone (Compound) and Medrysone (Compound) resembles Drospirenone (Compound)
Lenalidomide (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Medrysone (Compound) and Medrysone (Compound) resembles Drospirenone (Compound)
Lenalidomide (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is regulated by PTGS2 (Gene) and PTGS2 (Gene) is bound by Drospirenone (Compound)